This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $882,816 to Rutgers, The State University, to conduct research on improving patient-centered outcomes for individuals with co-occurring post-traumatic stress disorder (PTSD) and substance use disorders (SUD). The key products and services to be delivered through this 4-year award include: (1) new analyses on recovery-focused outcomes to...
This Project Grant award, valued at $4,208,345.00 and effective from September 30, 2024 to September 29, 2028, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports a "Hybrid 1 Effectiveness-Implementation Trial of Partner-Assisted Prolonged Exposure for PTSD" at the Regents of the University of Minnesota, a prominent land-grant research institution. This medical research project aims to...
This $1,235,474 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program supports research to investigate the role of a thalamic-hippocampal pathway in suppressing and extinguishing contextual fear memories associated with post-traumatic stress disorder (PTSD). The project aims to use advanced neuroimaging and optogenetic techniques in head-fixed mice to elucidate how the nucleus reuniens region of the thalamus...
This Project Grant award of $2,384,097, provided by the Defense Health Agency through the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding a hybrid experimental clinical trial to determine the optimal sequencing of interventions to maximize the effectiveness of PTSD treatment. The primary awardee, The University of Texas Health Science Center at San Antonio, will conduct this research with a planned completion date of August 2028. The project involves two...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is funding research at the University of California, San Diego (UCSD) to comprehensively evaluate the relationship between trauma exposure and substance use among Americans from childhood through adulthood. The $158,246 award, effective July 1, 2025 through June 30, 2027, will support the investigation of how situational stress factors moderate...
This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $610,152 to Duke University to study the structural and functional architecture of cortico-cerebellar systems in post-traumatic stress disorder (PTSD). The key objectives are to investigate the influence of PTSD, trauma exposure, and PTSD symptom clusters on the functional connectivity of cerebellar subregions, examine the structural...
This $2,210,781 federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research to determine the molecular and cellular mechanisms in A13 dopaminergic cells in the zona incerta that contribute to extinction learning. The research aims to advance the understanding of how dopaminergic signaling modulates extinction learning, which is a core deficit in post-traumatic stress disorder (PTSD). The...
This federal Project Grant award, valued at $3,141,404.00 and issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a randomized controlled trial to evaluate the efficacy of combined cognitive processing therapy and stellate ganglion blocks for the treatment of post-traumatic stress disorder (PTSD). The award was granted to Rush University Medical Center, a prominent academic medical center in Chicago, Illinois, to conduct this...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and evaluate an adapted version of Written Exposure Therapy (WET) for treating posttraumatic stress disorder (PTSD) among individuals with opioid use disorder (OUD) in residential substance use disorder (SUD) treatment settings. The $798,605 award will fund a multi-site study to create and test the adapted "Written Exposure in...
This federal Project Grant award, funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), will support a research project titled "EARLY-PHASE PSYCHOSIS: PRACTICE-BASED RESEARCH TO IMPROVE TREATMENT OUTCOMES". The $1,659,568 award, effective June 2, 2025 through May 31, 2030, will enable the awardee, The Feinstein Institutes for Medical Research, to enroll an additional 625 participants from 13 clinics across 6 states in...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $1,462,939.00 to conduct a hybrid effectiveness-implementation trial of massed prolonged exposure (M-PE) treatment for post-traumatic stress disorder (PTSD) comorbid with substance use disorder (SUD). The primary objectives are to compare the effectiveness of M-PE versus treatment as usual (TAU) in reducing PTSD symptoms and substance use among 168 SUD patients with PTSD receiving intensive outpatient treatment at Gateway Community Services, Inc. The award period is from September 3, 2024 to June 30, 2029. The project includes sub-awards to the University of Minnesota, Gateway Community Services, and UC San Diego to support various aspects of the research, such as conducting the clinical trial, providing the M-PE intervention, and evaluating implementation factors.